Physician profile
Jeffrey David Benner
NPI 1235137878
$95,121.97
in general payments reported to CMS, 2019-2025
10 companies · $34K in 2025
The $34K reported for 2025 was more than what 98% of Ophthalmology providers received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $721 · 2020: $561 · 2021: $1,288 · 2022: $4,793 · 2023: $20K · 2024: $34K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $87K · Food and Beverage: $477.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $87,281.68 |
| Food and Beverage | $476.69 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oculus Surgical INC. | $90,384.55 | 2022-2025 | Cbc Lens |
| US Retina LLC | $3,641.20 | 2019-2022 | |
| Genentech USA, INC. | $431.19 | 2019-2023 | Vabysmo |
| Aerie Pharmaceuticals, INC. | $139.39 | 2019-2021 | |
| Braeburn INC. | $124.80 | 2024 | Brixadi |
| Indivior INC. | $120.84 | 2025 | Sublocade |
| E.R. Squibb & Sons, L.L.C. | $120.69 | 2025 | Cobenfy |
| Regeneron Healthcare Solutions, INC. | $85.64 | 2019-2023 | Eylea |
| Novartis Pharmaceuticals Corporation | $51.52 | 2021 | |
| Eyepoint US, INC. | $22.15 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$131,530.32 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Benner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.